Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Biomatics Capital
BioCentury | Feb 23, 2021
Deals
Beam adds ex-hepatic delivery tech to base editing toolkit with Guide buyout
Beam will take advantage of a months-long run-up in its share price to add a key base editing delivery technology via its takeout of privately held Guide Therapeutics, providing an early exit for
BioCentury | Jan 29, 2021
Finance
Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more
Gene and cell therapy company Sana Biotechnology Inc. proposed terms for an IPO on NASDAQ in which it hopes to sell 15 million shares at $20-$23. At the midpoint, the company would raise $322.5
BioCentury | Aug 21, 2020
Product Development
How AI can meet the moment
AI experts weigh in on what’s needed to make the most of the pandemic’s accelerating effects
BioCentury | Jun 25, 2020
Deals
June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla
BioCentury | Jun 11, 2020
Finance
Insiders lead, crossovers join in gene editing play Verve’s $63M round
GV leads A2 round, which came at a ‘very good step-up’ in valuation
BioCentury | Mar 5, 2020
Emerging Company Profile
AiCure: harnessing AI to boost adherence
AiCure is applying AI to visual, vocal and behavioral patient data to optimize trial adherence
BioCentury | Jan 10, 2020
Financial News
Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas
BioCentury | Nov 9, 2019
Financial News
Nov. 8 Financial Quick Takes: First day of trading for BrightGene, Tot; plus argenx, Agios and AiCure
BioCentury | Nov 8, 2019
Financial News
eGenesis pushes to bring pig organ transplants to humans with $100M series B
BioCentury | Jun 13, 2019
Finance
With $76M series B, BlackThorn looks to build out neurobehavioral platform
How BlackThorn rebounded from a January clinical setback to raise $76 million to develop its targeted therapies for neurobehavioral disorders
Items per page:
1 - 10 of 37